Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",body mass,,RS:0000261,E3/Ztm,male,103 days to 56 days,3,,CMO:0000420,body weight gain,,,,39,g,5.1962,9.0,MMO:0000016,body weighing method,,0.0,,,,,spinal cord homogenate (10 mg) ,69957,spinal cord homogenate (10 mg) 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",body mass,,RS:0000261,E3/Ztm,female,103 days to 56 days,12,,CMO:0000420,body weight gain,,,,80,g,0.866,3.0,MMO:0000016,body weighing method,,0.0,,,,,spinal cord homogenate (10 mg) ,69956,spinal cord homogenate (10 mg) 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000261,E3/Ztm,female,103 days to 56 days,12,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69955,spinal cord homogenate (10 mg) 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000261,E3/Ztm,male,103 days to 56 days,3,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69954,spinal cord homogenate (10 mg)